RT Journal Article
T1 Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort.
A1 Hernández-Fernández, Carlos Pelayo
A1 Carretero, Gregorio
A1 Rivera, Raquel
A1 Ferrándiz, Carlos
A1 Daudén, Esteban
A1 de Cueva, Pablo
A1 Belinchón, Isabel
A1 Gómez-García, Francisco Javier
A1 Herrera-Acosta, Enrique
A1 Ruiz-Genao, Diana P
A1 Ferrán, Marta
A1 Alsina, Mercé
A1 Baniandrés-Rodríguez, Ofelia
A1 Sánchez-Carazo, José Luis
A1 Botella-Estrada, Rafael
A1 Sahuquillo-Torralba, Antonio
A1 Rodríguez, Lourdes
A1 Vilar-Alejo, Jaime
A1 García-Donoso, Carmen
A1 Carrascosa, José M
A1 Llamas-Velasco, Mar
A1 Herrera-Ceballos, Enrique
A1 López-Estebaranz, Jose Luis
A1 Pujol-Marco, Conrad
A1 Descalzo, Miguel Angel
A1 Garcia-Doval, Ignacio
A1 the BIOBADADERM Study Group, 
K1 biological therapy
K1 drug prescription
K1 drug safety
K1 gender bias
K1 psoriasis
K1 sex
K1 sex bias
K1 gender
AB The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be prescribed biologics. There were no differences between men and women in effectiveness of therapy, measured in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.
YR 2021
FD 2021-01-04
LK http://hdl.handle.net/10668/16723
UL http://hdl.handle.net/10668/16723
LA en
DS RISalud
RD Apr 7, 2025